Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Dougherty

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 13, 1999
Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials. The Multiple Sclerosis Collaborative Research Group (MSCRG)D E Goodkin, R L Priore, K E Wende, et al.
Journal of Neuroimmunology|June 23, 1999
Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research GroupR A Rudick, D L Cookfair, N A Simonian, et al.
Neurology|March 21, 2002
Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. 1997R A Rudick, D E Goodkin, L D Jacobs, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 13, 1999
Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials. The Multiple Sclerosis Collaborative Research Group (MSCRG)D E Goodkin, R L Priore, K E Wende, et al.
Journal of Neuroimmunology|June 23, 1999
Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research GroupR A Rudick, D L Cookfair, N A Simonian, et al.
Neurology|March 21, 2002
Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. 1997R A Rudick, D E Goodkin, L D Jacobs, et al.
Pageof 7